About Cavernous Angioma; also known as Cerebral Cavernous Malformation (CCM), Cavernous Hemangioma, and Cavernoma
Cavernous Angioma is a blood vessel disorder that affects up to one in two hundred people in the general population. Cavernous Angioma is characterized by the presence of vascular lesions that develop and grow within the brain and spinal cord. These lesions are composed of thin malformed blood vessels that are weak and prone to leakage and rupture. Bleeding from these lesions causes the symptoms of Cavernous Angioma that range from persistent headaches and focal neurological deficits to severe seizures and hemorrhagic stroke.
Cavernous Angioma may be transmitted in a familial form by inheritance of a genetic mutation in one of three disease causing genes, CCM1, CCM2 or CCM3. Affected individuals with the inherited form of the illness typically develop multiple lesions. Single lesions are typical of patients with the sporadic (non-genetic) form of the illness.
Currently the only treatment for Cavernous Angioma is brain and/or spinal surgery. The goal of the International Cavernous Angioma Patient Registry is to facilitate discovery and development of a non-invasive pharmacological treatment of the illness.
The International Cavernous Angioma Patient Registry is developed and supported by Angioma Alliance; a patient-directed network founded in 2002 and dedicated to improving the lives of those affected by Cavernous Angioma. For more information about our support programs or to get involved visit us at www.angioma.org.